520 related articles for article (PubMed ID: 12700703)
21. Chronic phencyclidine treatment induces long-lasting glutamatergic activation of VTA dopamine neurons.
Uramura K; Maejima Y; Shimomura K; Santoso P; Katsuda S; Kobayashi D; Jodo E; Kodaira M; Otgon-Uul Z; Yang Y; Sakuma K; Takigawa M; Hazama A; Yada T
Neurosci Lett; 2014 Apr; 564():72-7. PubMed ID: 24525246
[TBL] [Abstract][Full Text] [Related]
22. Alterations of prefrontal cortex GABAergic transmission in the complex psychotic-like phenotype induced by adolescent delta-9-tetrahydrocannabinol exposure in rats.
Zamberletti E; Beggiato S; Steardo L; Prini P; Antonelli T; Ferraro L; Rubino T; Parolaro D
Neurobiol Dis; 2014 Mar; 63():35-47. PubMed ID: 24200867
[TBL] [Abstract][Full Text] [Related]
23. Blockade of NMDA receptors in the prefrontal cortex increases dopamine and acetylcholine release in the nucleus accumbens and motor activity.
Del Arco A; Segovia G; Mora F
Psychopharmacology (Berl); 2008 Dec; 201(3):325-38. PubMed ID: 18751970
[TBL] [Abstract][Full Text] [Related]
24. Involvement of gamma-aminobutyric acid neurotransmission in phencyclidine-induced dopamine release in the medial prefrontal cortex.
Yonezawa Y; Kuroki T; Kawahara T; Tashiro N; Uchimura H
Eur J Pharmacol; 1998 Jan; 341(1):45-56. PubMed ID: 9489855
[TBL] [Abstract][Full Text] [Related]
25. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic.
Abekawa T; Ito K; Koyama T
Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):261-71. PubMed ID: 17458542
[TBL] [Abstract][Full Text] [Related]
26. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC
Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
[TBL] [Abstract][Full Text] [Related]
27. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats.
Abekawa T; Ito K; Nakagawa S; Koyama T
Psychopharmacology (Berl); 2007 Jun; 192(3):303-16. PubMed ID: 17340116
[TBL] [Abstract][Full Text] [Related]
28. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex.
Lecourtier L; Homayoun H; Tamagnan G; Moghaddam B
Biol Psychiatry; 2007 Oct; 62(7):739-46. PubMed ID: 17511968
[TBL] [Abstract][Full Text] [Related]
29. Behavioral arousal and increased dopamine efflux after blockade of NMDA-receptors in the prefrontal cortex are dependent on activation of glutamatergic neurotransmission.
Feenstra MG; Botterblom MH; van Uum JF
Neuropharmacology; 2002 May; 42(6):752-63. PubMed ID: 12015201
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of D2 receptors in the prefrontal cortex reduces PCP-induced hyperactivity, acetylcholine release and dopamine metabolism in the nucleus accumbens.
Del Arco A; Mora F; Mohammed AH; Fuxe K
J Neural Transm (Vienna); 2007 Feb; 114(2):185-93. PubMed ID: 16897609
[TBL] [Abstract][Full Text] [Related]
31. Neonatal phencyclidine treatment selectively attenuates mesolimbic dopamine function in adult rats as revealed by methamphetamine-induced behavior and c-fos mRNA expression in the brain.
Semba J; Tanaka N; Wakuta M; Suhara T
Synapse; 2001 Apr; 40(1):11-8. PubMed ID: 11170217
[TBL] [Abstract][Full Text] [Related]
32. Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia.
Zuo D; Bzdega T; Olszewski RT; Moffett JR; Neale JH
J Biol Chem; 2012 Jun; 287(26):21773-82. PubMed ID: 22570482
[TBL] [Abstract][Full Text] [Related]
33. Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release.
Homayoun H; Stefani MR; Adams BW; Tamagan GD; Moghaddam B
Neuropsychopharmacology; 2004 Jul; 29(7):1259-69. PubMed ID: 15010696
[TBL] [Abstract][Full Text] [Related]
34. Amygdala regulation of nucleus accumbens dopamine output is governed by the prefrontal cortex.
Jackson ME; Moghaddam B
J Neurosci; 2001 Jan; 21(2):676-81. PubMed ID: 11160446
[TBL] [Abstract][Full Text] [Related]
35. Involvement of a dysfunctional dopamine-D1/N-methyl-d-aspartate-NR1 and Ca2+/calmodulin-dependent protein kinase II pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine.
Mouri A; Noda Y; Noda A; Nakamura T; Tokura T; Yura Y; Nitta A; Furukawa H; Nabeshima T
Mol Pharmacol; 2007 Jun; 71(6):1598-609. PubMed ID: 17344353
[TBL] [Abstract][Full Text] [Related]
36. N-Methyl-d-aspartate Modulation of Nucleus Accumbens Dopamine Release by Metabotropic Glutamate Receptors: Fast Cyclic Voltammetry Studies in Rat Brain Slices in Vitro.
Yavas E; Young AM
ACS Chem Neurosci; 2017 Feb; 8(2):320-328. PubMed ID: 28121123
[TBL] [Abstract][Full Text] [Related]
37. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists.
Chartoff EH; Heusner CL; Palmiter RD
Neuropsychopharmacology; 2005 Jul; 30(7):1324-33. PubMed ID: 15688082
[TBL] [Abstract][Full Text] [Related]
38. Glutamate receptors in nucleus accumbens mediate regionally selective increases in cortical acetylcholine release.
Zmarowski A; Sarter M; Bruno JP
Synapse; 2007 Mar; 61(3):115-23. PubMed ID: 17146770
[TBL] [Abstract][Full Text] [Related]
39. Subchronic phencyclidine administration increases mesolimbic dopaminergic system responsivity and augments stress- and psychostimulant-induced hyperlocomotion.
Jentsch JD; Taylor JR; Roth RH
Neuropsychopharmacology; 1998 Aug; 19(2):105-13. PubMed ID: 9629564
[TBL] [Abstract][Full Text] [Related]
40. Nitric oxide signaling in the medial prefrontal cortex is involved in the biochemical and behavioral effects of phencyclidine.
Fejgin K; Pålsson E; Wass C; Svensson L; Klamer D
Neuropsychopharmacology; 2008 Jul; 33(8):1874-83. PubMed ID: 17895915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
